Is NCT07290244 recruiting in Glendale, CA?

Yes, NCT07290244 is currently recruiting participants at its Glendale, CA location. This open angle glaucoma (oag) clinical trial is actively enrolling qualified participants.

How do I join the open angle glaucoma (oag) clinical trial in Glendale?

To join this clinical trial in Glendale, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

Is participation in this Glendale clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

Open Angle Glaucoma (OAG) Clinical Trial in Glendale, CA

About This Open Angle Glaucoma (OAG) Study in Glendale

The goal of this clinical trial is to evaluate the safety and tolerability of a single dose of ER-100 in adults with optic nerve conditions, specifically Open Angle Glaucoma (OAG) and Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION). The main questions it aims to answer are: * Is ER-100 safe when given as a single dose to people with OAG or NAION * What side effects may occur, if any, after taking ER-100? Participants will: * Receive a single dose of ER-100 * Undergo safety assessments including detailed eye examination and laboratory tests * Provide body fluid samples (tears, saliva, feces, urine) to help researchers understand how the drug is processed and cleared from the body * Complete questionnaires about their quality of life * Be followed for up to 5 years to monitor long-term health and vision outcomes

Sponsor: Life Biosciences Inc.

Who Can Participate

Inclusion Criteria

Have clear eye structures and be able to have your pupils safely dilated so the doctor can examine the back of your eye.

Able to understand the study and sign a consent form.

Be between 40 and 85 years old.

Willing and able to follow the study schedule, including all visits and tests, and speak a language for which the study materials are available.

If a participant can become pregnant, must agree to use a condom and one highly effective form of birth control during sex for at least 4 months after receiving the study drug (ER-100). For participants with open-angle glaucoma (OAG):

Diagnosis of open-angle glaucoma in the study eye.

Eye pressure must be less than 30 mmHg, measured with a standard test.

Visual field test must show moderate to advanced vision loss (MD score between -6 and -20 dB).

Not expected to need glaucoma surgery in the study eye within 2 months after receiving ER-100.

Have reasonably good vision in the study eye (at least 20/80 on a standard eye chart). For participants with NAION (non-arteritic anterior ischemic optic neuropathy):

Had a sudden, painless loss of vision in one eye within 14 days before receiving ER-100, confirmed by a specialist. Having had NAION in the other eye is okay.

The affected eye must show swelling of the optic nerve.

Visual field test must show vision loss consistent with optic nerve damage (MD worse than -3.0 dB).

If only one eye is affected, there must be a difference in pupil response between the two eyes.

Have vision in the affected eye between 20/40 and 2/500 on a standard eye chart.

Exclusion Criteria

History of optic neuritis (inflammation of the optic nerve) or repeated episodes of eye inflammation (uveitis) not caused by injury or surgery.

Allergic reactions to tetracycline antibiotics or steroid medications.

Moderate to severe cataracts, macular problems, or corneal issues that could interfere with eye testing.

Unable to keep your eyes focused on a target during testing.

Had cataract surgery or other eye surgery (including laser procedures) within 3 months before receiving the study drug.

Had cancer (except for basal cell skin cancer) within the past 5 years.

Have Type 1 diabetes, or poorly controlled Type 2 diabetes (A1c greater than 7 despite treatment).

Have memory or thinking problems that prevent you from understanding the study or completing the required tests.

Pregnant or breastfeeding.

Have a weakened immune system, including a history of organ transplant, or test positive for HIV, hepatitis B or C, or tuberculosis.

Have any other condition that, in the opinion of the study doctor, could increase your risk from the study drug or procedures, affect the study results, or make it hard for you to complete the study.

Have macular disease, advanced diabetic eye disease, or other eye conditions that limit vision in the study eye.

Eye pressure at screening is 30 mmHg or higher.

Taking certain medications (warfarin, dilantin, carbamazepine, or barbiturates) within 14 days before starting the study or during the first 8 weeks.

Have any other eye or vision problem that, in the opinion of the study doctor, could affect safety or interfere with vision testing.

Have previously received any gene therapy using adeno-associated virus (AAV). Additional Exclusion Criteria for Participants with Open-Angle Glaucoma (OAG): \- Diagnosed with glaucoma before age 40. Additional Exclusion Criteria for Participants with NAION:

Show signs of giant cell arteritis (a type of blood vessel inflammation), based on abnormal blood tests.

Had NAION start in both eyes at the same time.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Glendale?

Yes, this clinical trial (NCT07290244) has an active research site in Glendale, CA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Open Angle Glaucoma (OAG) Treatment Options in Glendale, CA

If you're searching for open angle glaucoma (oag) treatment options in Glendale, CA, this clinical trial (NCT07290244) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Glendale research site is actively enrolling participants for this clinical trial. You'll receive care from experienced open angle glaucoma (oag) specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all open angle glaucoma (oag) clinical trials near you to find additional studies recruiting in your area.

Open Angle Glaucoma (OAG) Clinical Trial in Glendale, CA

Expert Care in Glendale

IRB Approved

No-Cost Care

Apply for This Glendale Location

Why Participate?

Simple Process